SATB2 (EP281) Rabbit Monoclonal Primary Antibody

SATB2
Nuclear expression by anti-SATB2 is highlighted on colorectal carcinoma.

SATB2 (EP281) Rabbit Monoclonal Primary Antibody

Specialties: Gastrointestinal (GI) Pathology

Updated: 2018-06-29 11:24:07

Special AT-rich sequence-binding protein 2 (SATB2) is a recently described marker that functions as a nuclear matrix-associated transcription factor. It has been reported that SATB2, in combination with CK20, could identify almost all colorectal carcinomas,1 including poorly differentiated colorectal carcinomas.2 Upper gastrointestinal (GI) carcinomas and pancreatic ductal carcinomas are usually negative for SATB2,1 and ovarian carcinomas, lung adenocarcinomas, and adenocarcinomas from other origin are rarely positive for SATB2.1,2 Therefore, SATB2 is a good marker for identifying a carcinoma of colorectal origin when working on a tumor of unknown primary.1,2,5 Another potential utility of SATB2 is to identify neuroendocrine neoplasms/carcinomas of the left colon and rectum because SATB2 is usually negative in other neuroendocrine neoplasms of the GI tract, pancreas, and lung.3 More recently, it has been shown in literature that SATB2 is a sensitive marker for tumors with osteoblastic differentiation.4

  1. Mangnusso K, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinoma. Am J Surg Pathol. 2011; 35:937-48.
  2. Lin F, et al. Cadherin17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine. Arch Pathol Lab Mad. 2014; 138:1015-26.
  3. Li Z, et al. SATB2 is a highly sensitive marker for hindgut well-differentiated neuroendocrine tumors. Int J Clin Exp Pathol. 2015; 8:7072-82.
  4. Conner JR, et al. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumors. Histopathology. 2013; 63:182-93
  5. Dragomir A, et al. the role of SATB2 as a diagnostic marker for tumors of colorectal origin. Am J Clin Pathol 2014; 141:630-38.

Specifications


  • Reactivity: paraffin
  • Control: Colon adenocarcinoma (Nuclear); Colon (Nuclear)
  • Dilution Range: 1:25-1:100 *

Package Inserts


IFU SDS

Ordering Information

For in vitro diagnostic (IVD) use in USA

25.0 mL predilute ready-to-use384R-10
0.1 mL concentrate384R-14
0.5 mL concentrate384R-15
1.0 mL concentrate384R-16
1.0 mL predilute ready-to-use384R-17
7.0 mL predilute ready-to-use384R-18

For in vitro diagnostic (IVD) use in Canada

25.0 mL predilute ready-to-use384R-10
0.1 mL concentrate384R-14
0.5 mL concentrate384R-15
1.0 mL concentrate384R-16
1.0 mL predilute ready-to-use384R-17
7.0 mL predilute ready-to-use384R-18

For in vitro diagnostic (IVD) use in Europe

25.0 mL predilute ready-to-use384R-10
0.1 mL concentrate384R-14
0.5 mL concentrate384R-15
1.0 mL concentrate384R-16
1.0 mL predilute ready-to-use384R-17
7.0 mL predilute ready-to-use384R-18

For research use only (RUO) in Japan

0.1 mL concentrate (RUO)381R-14-RUO
25.0 mL predilute ready-to-use (RUO)384R-10-RUO
0.5 mL concentrate (RUO)384R-15-RUO
1.0 mL concentrate (RUO)384R-16-RUO
1.0 mL predilute ready-to-use (RUO)384R-17-RUO
7.0 mL predilute ready-to-use (RUO)384R-18-RUO

 

To request information on this product in additional countries, please click the button below.

Request More Information